In Vivo Prevention of Murine GVHD
小鼠 GVHD 的体内预防
基本信息
- 批准号:10610863
- 负责人:
- 金额:$ 58.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Abstract
Our overall goals are focus on the prevention and treatment of graft-vs-host disease (GVHD) via innate lymphoid
type 2 cell (ILC2) anti-inflammatory and tissue reparative properties. We found that host ILC2s in are eliminated
by total body irradiation {TBI} or chemotherapy and remain depleted for at >/=90 days. This finding is highly
relevant as there is an inverse correlation between peripheral blood activated ILC2s and GVHD. As such. we
sought to determine whether supplemental infusion of mature donor ILC2s could be used to prevent murine
GVHD. We showed for the first time that donor ILC2s could prevent or partially treat GVHD in an amphiregulin
(AREG) dependent process. Whether AREG or ILC2 direct contact with intestinal stem cells {ISC) supports small
intestine epithelial cell repair in TBI treated mice or organoids is unknown. Additionally, third-party ILC2 infusion
also significanUy reduced murine GVHD lethality. lmportanUy for translational purposes, we found ILC2s to be
relatively steroid resistant. Peri-BMT {bone marrow transplant) IL-33 increased ST2/IL33R+ ILC2s at BMT day
0 and reduced GVHD. Ko mice had accelerated GVHD; IL-33 given pre-BMT prevented the full lLC2 loss. IL-33
ko recipients have hypo-proliferative epithelial cells, reduced ISCs and Paneth cells, and smaller crypt height
and numbers. Ex vivo intestine organoid culture modeling revealed that IL-33 coordinated regeneration by
inducing epidermal growth factor (EGF), significantly reduced by TBI. EGF restored ISC deficiency, uncovering
a gut repair IL-33/EGF loop between ISCs and Paneth cells. Donor IL-13 ko ILC2s or host IL 13Ra ko mice had
reduced GVHD. ILC2 IL 13 supports both ST2+ tuft cells and goblet cells. Tuft cells produce IL-25 driving ILC2
production and survival. TBI markedly reduced tuft cells for :!:38 days and ko recipients had a striking increase
in GVHD. When given to wildtype mice exogenous IL-25 significantly reduced GVHD. Consequences of ko of
tuft cells (and ILC2s) on donor T cell expansion, trafficking and function are unknown. The role of IL-25 and
IL 17RB has not been examined. We will address the dynamics and interplay between ILC2, IL-33 and
host intestinal cells (tuft cells, ISCs, Paneth cells) after TBI and during GVHD.
Aim 1 will test the hypothesis that: Donor ILC2 repopulation fails due to destruction of ILC2 BM niche
that supports ILC2s. In vitro pre-lLC2 differentiation, maturation and expansion ± proinflammatory
cytokines and ILC2 supporting cytokines will be studied. GATA3-GFPhi pre-lLC2s/mature ILC2s transfer
into lethally irradiated congenic BMT recipients will provide data on the differential ability to repopulate the
BM. If the BM cannot support pre-lLC2s/lLC2s, we will study stem cell deficient mice. Aim 2 will test the
hypothesis that: Pre-lLC2s/lLC2s and their secreted products have direct effects on intestinal cell subsets.
Intestinal organoid cultures from wild-type and IL-33 ko mice with syngeneic Tregs and ILC2s will measure
organoid size, number, and gene expression related to proliferation, cell cycle regulation, and specific
epithelial lineage markers under homeostasis or after TBI. Anti-AREG mAbs or co-cultures with AREG ko
lymphocytes will be characterized for promoting epithelial regeneration. Aim 3 will test the hypothesis that: Tuft
cells are essential for ILC2 development and survival via an ILC2 release of IL-13 that stimulates tuft cells to
release IL-25 that causes ILC2 proliferation (aim 3). Tuft cell and ILC2 ko hosts have accelerated GVHD. We
hypothesize that IL-25 effects are due to direct stimulation of ILC2s or alternatively, with donor IL-17RB+ T
cells.
Significance. Studies in the R37 extension phase will provide fundamental information as to the mechanisms
by which peri-BMT IL-33 diminish GVHD lethality via effects on ST2+ host ILC2s and regulatory T cells,
both of which produce AREG, and the EGF/IL-33 loop that occurs between ISCs and Paneth cells resulting in
small intestine repair. Further, the key role of host ILC2s in subduing GVHD, the nature of post-BMT ILC2
deficiency that occurs after pre-BMT conditioning regimens and predisposes patients to GVHD, and the
essential requirement for tuft cells or their product, IL-25 will be elucidate. LasUy, critical insights will be
gained as to the inability of pre-lLC2s generation, gut migration or differentiation.
Translational Impact: The efficacy of donor and third-party ILC2 infusion in preventing and treating GVHD
support our planned human ILC2 clinical trial, funded via other auspices, that will infuse "off-the-shelf' third
party ILC2s to treat steroid refractory gut GVHD, that portends a particularly poor prognosis, in a 2-
institutional study at the University of Minnesota and UNC-CH.
摘要
我们的总体目标是通过先天性淋巴结转移预防和治疗移植物抗宿主病(GVHD)。
2型细胞(ILC 2)抗炎和组织修复特性。我们发现,宿主ILC 2在
通过全身照射{TBI}或化疗,并保持耗尽>/=90天。这一发现高度
相关,因为外周血活化的ILC 2和GVHD之间存在负相关。就像这样。我们
试图确定是否可以使用成熟供体ILC 2的补充输注来预防鼠
GVHD。我们首次证明了供体ILC 2可以预防或部分治疗双调蛋白中的GVHD。
(AREG)依赖过程。AREG或ILC 2与肠干细胞(ISC)的直接接触是否支持小的
TBI处理的小鼠或类器官中的肠上皮细胞修复是未知的。此外,第三方ILC 2输注
也显著降低鼠GVHD致死率。为了翻译的目的,我们发现ILC 2是
对类固醇有抵抗力BMT(骨髓移植)周IL-33在BMT日增加ST 2/IL 33 R + ILC 2
0和减少GVHD。Ko小鼠具有加速的GVHD;给予预BMT的IL-33防止了完全的ILC 2损失。IL-33
ko受体的上皮细胞增殖低下,ISC和潘氏细胞减少,隐窝高度降低
和数字离体肠类器官培养模型显示,IL-33协调再生,
诱导表皮生长因子(EGF),TBI显著降低。EGF修复了ISC缺陷,
ISCs和Paneth细胞之间的肠修复IL-33/EGF环。供体IL-13 ko ILC 2或宿主IL-13 Ra ko小鼠具有
减少GVHD。ILC 2 IL 13支持ST 2+簇状细胞和杯状细胞。簇细胞产生IL-25驱动ILC 2
生产与生存。TBI显著减少了以下的毛簇细胞:38天和ko接收者有显着增加
在GVHD。当给予野生型小鼠外源性IL-25时,显著降低GVHD。科的后果
簇细胞(和ILC 2)对供体T细胞扩增、运输和功能的影响是未知的。IL-25的作用,
IL 17 RB未被检测。我们将讨论ILC 2,IL-33和IL-10之间的动态和相互作用。
TBI后和GVHD期间的宿主肠细胞(簇状细胞、ISC、潘氏细胞)。
目的1将检验以下假设:由于ILC 2 BM生态位的破坏,供体ILC 2再增殖失败
支持ILC 2。体外前-ILC 2分化、成熟和扩增±促炎
将研究细胞因子和ILC 2支持细胞因子。GATA 3-GFPhi前ILC 2/成熟ILC 2转移
致死性照射的同基因BMT受体将提供关于重新填充
BM。如果BM不能支持pre-ILC 2/ILC 2,我们将研究干细胞缺陷小鼠。目标2将测试
Pre-ILC 2/ILC 2及其分泌产物对肠细胞亚群具有直接作用。
来自野生型和具有同基因Tcl 3和ILC 2的IL-33 ko小鼠的肠类器官培养物将测量
类器官的大小、数量和与增殖、细胞周期调节和特异性
上皮谱系标志物。抗AREG mAb或与AREG ko共培养
淋巴细胞的特征在于促进上皮再生。目标3将检验以下假设:
细胞通过ILC 2释放IL-13对ILC 2的发育和存活至关重要,IL-13刺激簇细胞,
释放导致ILC 2增殖的IL-25(目的3)。簇状细胞和ILC 2 ko宿主具有加速的GVHD。我们
假设IL-25作用是由于ILC 2的直接刺激或供体IL-17 RB + T的刺激
细胞
意义R37扩展阶段的研究将提供有关机制的基本信息
通过该方法,外周BMT IL-33通过对ST 2+宿主ILC 2和调节性T细胞的作用降低GVHD致死率,
两者都产生AREG,并且在ISCs和Paneth细胞之间发生的EGF/IL-33环导致
小肠修复此外,宿主ILC 2在抑制GVHD中的关键作用,BMT后ILC 2的性质,
在预骨髓移植预处理方案后发生的缺陷,使患者易患GVHD,
将阐明毛丛细胞或其产物IL-25基本要求。Lasuy,批判性的见解将是
获得了关于不能产生pre-ILC 2、肠道迁移或分化的结论。
转化影响:供体和第三方ILC 2输注在预防和治疗GVHD中的疗效
支持我们计划的人类ILC 2临床试验,通过其他赞助,这将注入“现成的”第三
在一项2-
在明尼苏达大学和UNC-CH进行机构研究。
项目成果
期刊论文数量(94)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance.
- DOI:10.1084/jem.20182232
- 发表时间:2021-01-04
- 期刊:
- 影响因子:0
- 作者:Tan CL;Kuchroo JR;Sage PT;Liang D;Francisco LM;Buck J;Thaker YR;Zhang Q;McArdel SL;Juneja VR;Lee SJ;Lovitch SB;Lian C;Murphy GF;Blazar BR;Vignali DAA;Freeman GJ;Sharpe AH
- 通讯作者:Sharpe AH
Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.
- DOI:10.4049/jimmunol.1200858
- 发表时间:2012-08-15
- 期刊:
- 影响因子:0
- 作者:Fulton LM;Carlson MJ;Coghill JM;Ott LE;West ML;Panoskaltsis-Mortari A;Littman DR;Blazar BR;Serody JS
- 通讯作者:Serody JS
Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model.
- DOI:10.1182/blood.v96.3.1157
- 发表时间:2000-08
- 期刊:
- 影响因子:20.3
- 作者:D. Vallera;D. Kuroki;A. Panoskaltsis‐Mortari;D. Buchsbaum;B. Rogers;B. Blazar
- 通讯作者:D. Vallera;D. Kuroki;A. Panoskaltsis‐Mortari;D. Buchsbaum;B. Rogers;B. Blazar
Current Concepts and Advances in Graft-Versus-Host Disease Immunology.
- DOI:10.1146/annurev-immunol-102119-073227
- 发表时间:2021-04-26
- 期刊:
- 影响因子:29.7
- 作者:Hill GR;Betts BC;Tkachev V;Kean LS;Blazar BR
- 通讯作者:Blazar BR
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.
- DOI:10.1182/bloodadvances.2022007611
- 发表时间:2023-09-12
- 期刊:
- 影响因子:7.5
- 作者:Buxbaum, Nataliya P.;Socie, Gerard;Hill, Geoffrey R.;Macdonald, Kelli P. A.;Tkachev, Victor;Teshima, Takanori;Lee, Stephanie J.;Ritz, Jerome;Sarantopoulos, Stefanie;Luznik, Leo;Zeng, Defu;Paczesny, Sophie;Martin, Paul J.;Pavletic, Steven Z.;Schultz, Kirk R.;Blazar, Bruce R.
- 通讯作者:Blazar, Bruce R.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bruce R Blazar其他文献
Challenges and solutions for cellular therapy development in autoimmune diseases
自身免疫性疾病中细胞治疗发展的挑战与解决方案
- DOI:
10.1016/s2665-9913(24)00274-1 - 发表时间:
2024-11-01 - 期刊:
- 影响因子:16.400
- 作者:
Elizabeth R Volkmann;John Varga;Bruce R Blazar;Steven Z Pavletic - 通讯作者:
Steven Z Pavletic
Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)
- DOI:
10.1182/blood-2024-205130 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Lev Gorfinkel;Muna Qayed;Brandi Bratrude;Kayla Betz;Kyle Hebert;Sung W. Choi;Jeffrey Davis;Christine Duncan;Roger H. Giller;Michael S. Grimley;Andrew Harris;David A Jacobsohn;Nahal Lalefar;Nosha Farhadfar;Michael A. Pulsipher;Shalini Shenoy;Aleksandra Petrovic;Kirk R. Schultz;Gregory Yanik;Bruce R Blazar - 通讯作者:
Bruce R Blazar
IL-33 Induces Paneth Cell Production of EGF and Soluble ST2, Regulating Epithelial Regeneration after Intestinal Injury
- DOI:
10.1182/blood-2023-191189 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Marco Calafiore;YA-Yuan Fu;Paola Vinci;Viktor Arnhold;Winston Chang;Suze Jansen;Anastasiya Egorova;Shuichiro Takashima;Jason Kuttiyara;Takahiro Ito;Jonathan Serody;Susumu Nakae;Heth Turnquist;Johan van Es;Hans Clevers;Caroline A. Lindemans;Bruce R Blazar;Alan M. Hanash - 通讯作者:
Alan M. Hanash
Cyclosporine and Voclosporin Resistant Immune Effector Cells to Improve Outcomes after Stem Cell Transplantation
- DOI:
10.1182/blood-2023-180218 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Holly Wobma;Jiayi Dong;Francesca Alvarez Calderon;Xianliang Rui;Katherine Michaelis;Bruce R Blazar;Victor Tkachev;Ulrike Gerdemann;Leslie Kean - 通讯作者:
Leslie Kean
Mitochondrial Pyruvate Carrier Inhibition Mitigates Murine Chronic Graft Versus Host Disease By Attenuating the Germinal Center Reaction
- DOI:
10.1182/blood-2023-185200 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Fathima A Mohamed;Stephanie Y Rhee;Joanna Ly;Ethan G Aguilar;Haley Melin;Peter T Sage;Tanner Schumacher;Govindarajan Thangavelu;Michael C Zaiken;Juan Liu;Venkatram Mereddy;Jason W Locasale;Bruce R Blazar - 通讯作者:
Bruce R Blazar
Bruce R Blazar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bruce R Blazar', 18)}}的其他基金
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
- 批准号:
10763967 - 财政年份:2023
- 资助金额:
$ 58.97万 - 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
- 批准号:
10560605 - 财政年份:2021
- 资助金额:
$ 58.97万 - 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
- 批准号:
10092348 - 财政年份:2021
- 资助金额:
$ 58.97万 - 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
- 批准号:
10348683 - 财政年份:2021
- 资助金额:
$ 58.97万 - 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
- 批准号:
10305635 - 财政年份:2019
- 资助金额:
$ 58.97万 - 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
- 批准号:
10656502 - 财政年份:2019
- 资助金额:
$ 58.97万 - 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
- 批准号:
9888096 - 财政年份:2019
- 资助金额:
$ 58.97万 - 项目类别:
相似海外基金
Development of Teat-Dipping Nanoemulsion Loaded with Curcumin for Prevention of Intramammary Infection and Treatment of Mastitis as an Immune Stimulant
开发含有姜黄素的乳头浸渍纳米乳作为免疫兴奋剂预防乳房内感染和治疗乳腺炎
- 批准号:
24K09263 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Fellowship
Developing new tests and treatments to enable prevention of osteoarthritis.
开发新的测试和治疗方法以预防骨关节炎。
- 批准号:
MR/Y003470/1 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Fellowship
Transforming child mental health: co-designing, building and evaluating a digitally enabled, personalised, prevention pathway
改变儿童心理健康:共同设计、构建和评估数字化、个性化的预防途径
- 批准号:
MR/X034917/1 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Fellowship
Prediction, Monitoring and Personalized Recommendations for Prevention and Relief of Dementia and Frailty
预防和缓解痴呆症和衰弱的预测、监测和个性化建议
- 批准号:
10103541 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
EU-Funded
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Directed Grant
A digital tool to support pregnancy planning, preparation and prevention
支持怀孕计划、准备和预防的数字工具
- 批准号:
MR/Y503320/1 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Research Grant
Adaptation and Feasibility assessment of a primary suicide prevention intervention for school adolescents in Nigeria
尼日利亚学校青少年初级自杀预防干预措施的适应性和可行性评估
- 批准号:
MR/Y01958X/1 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Research Grant
PFI-TT: Chemical Synthesis of a Natural Product Family of Compounds for Tick-Targeted Prevention and Control
PFI-TT:用于蜱目标预防和控制的天然产物化合物家族的化学合成
- 批准号:
2345757 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Standard Grant
Integrating universal and tailored approaches across the continuum of mental health and substance use supports: Supporting the implementation and coordination of the Icelandic Prevention Model and Integrated Youth Services
在心理健康和药物滥用支持的连续过程中整合通用和量身定制的方法:支持冰岛预防模式和综合青年服务的实施和协调
- 批准号:
477940 - 财政年份:2024
- 资助金额:
$ 58.97万 - 项目类别:
Salary Programs